Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.
-
Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. NCCN Guidelines? Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 08; 22(6):366-375.
-
Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, Bukavina L, Szeto L, Hoffman-Censits JH, Mouw KW, Faltas BM, Grivas P, Ibragimova I, Porten SP, Van Allen EM, Geynisman DM, Parker DC, O'Neill JP, Drevik J, Christianson SS, Ginzburg S, Correa AF, Uzzo RG, Ross EA, Zibelman MR, Ghatalia P, Plimack ER, Kutikov A, Abbosh PH. Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precis Oncol. 2024 Jun; 8:e2300362.
-
Vlachou E, Johnson ? BA, Guancial E, Lombardo KA, Hoffman-Censits J. Frontline immune checkpoint inhibitors in patients = 90 years with advanced urothelial cancer: a single center experience. Can J Urol. 2024 Jun; 31(3):11875-11879.
-
Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024; 32(6):1031-1036.
-
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 05; 22(4):216-225.
-
Gomella LG. Is PSMA PET disrupting traditional prostate cancer staging and treatment? Can J Urol. 2024 Apr; 31(2):11814-11815.
-
Fung N, Fleseriu CM, Harley RJ, Khan NI, Kim S. Subcategorization of Perineural Invasion Stratifies Oral Cavity Squamous Cell Carcinoma Prognosis. Laryngoscope. 2024 Apr; 134(4):1656-1662.
-
Akin O, Woo S, Oto A, Allen BC, Avery R, Barker SJ, Gerena M, Halpern DJ, Gettle LM, Rosenthal SA, Taneja SS, Turkbey B, Whitworth P, Nikolaidis P. ACR Appropriateness Criteria? Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S187-S210.
-
Han C, Khan NI, Mady LJ. Prognosis. Otolaryngol Clin North Am. 2023 Apr; 56(2):389-402.
-
Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292). Ann Surg Oncol. 2023 Feb; 30(2):1099-1109.